The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
|
Activity Number:
|
610
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Thursday, August 4, 2011 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #302371 |
|
Title:
|
The Relationship Between CYP2C19 Genetic Polymorphisms, Clopidogrel Treatment, and Clinical Outcomes
|
|
Author(s):
|
Katy Simonsen*+ and Oksana Mokliatchouk and Eileen Emison
|
|
Companies:
|
Bristol-Myers Squibb and Bristol-Myers Squibb and Bristol-Myers Squibb
|
|
Address:
|
Rt 206 and Province Line Rd, Princeton, NJ, 08543,
|
|
Keywords:
|
cardiovascular ;
genetic ;
polymorphism ;
pharmaceutical ;
CYP2C19
|
|
Abstract:
|
Previous studies have found an association between clinical outcomes and CYP2C19 genetic polymorphisms in clopidogrel patients, without a placebo-controlled comparison. Using retrospective genotyping of two large placebo-controlled trials, we examined the differential effects of clopidogrel versus placebo on both ischemic and bleeding outcomes across genotypes. We found that examining the interaction between genotype and treatmentis essential to understanding the genetic effect. In addition, genotyping an uncommon gain-of-function polymorphism allowed us to identify a genotype with enhanced efficacy.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.